TheraRadar
Data updated: Mar 29, 2026

TEKAMLO

ALISKIREN HEMIFUMARATE
Approved 2010-08-26
Jump to: Indications Approvals Trials Competitors Safety Patents
1
Indication
--
Phase 3 Trials
15
Years on Market

Details

Status
Discontinued
First Approved
2010-08-26
Routes
ORAL
Dosage Forms
TABLET

Companies

Novartis
Active Ingredient: ALISKIREN HEMIFUMARATE , AMLODIPINE BESYLATE

TEKAMLO Approval History

Loading approval history...

What TEKAMLO Treats

1 FDA approvals

Originally approved for its first indication in 2010 .

  • Other (1)
🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...
⭐

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

ClinicalTrials.gov ↗ Pro

Full development history with FDA approval milestones

|
Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

TEKAMLO FDA Label Details

Pro

TEKAMLO Patents & Exclusivity

Latest Patent: Dec 2029

Patents (16 active)

US8613949 Expires Dec 21, 2029
+ 6 more patents
Source: FDA Orange Book

Want competitive intelligence?

See who's developing similar drugs and track their progress

View Pipeline Dashboard

Data Sources

FDA Approval: NDA022545 → Patents: FDA Orange Book → Trials: ClinicalTrials.gov →

Data sourced from official FDA and NIH databases. Click links to verify on original sources.